Video Series

Explore effective approaches in handling fatigue, insomnia, and financial difficulties of patients with desmoid tumors as experts highlight psychosocial support and treatment considerations for quality care.

Medical experts provide their final thoughts regarding key treatment considerations for CLL and SLL.

The panelists provide perspectives on critical aspects of the CLL and SLL treatment landscape.

Eric D. Donnenfeld, MD; underscores the significance of an FDA approved treatment for Demodex blepharitis as well as past alternative treatments.

Aaron Gerds, MD, MS, explores the FDA approval of momelotinib and its swift integration into National Comprehensive Cancer Network (NCCN) guidelines. He reviews different JAK inhibitors based on adverse effects and treatment goals, addressing potential treatment-related anemia in myelofibrosis.

Explore the multifaceted impact of desmoid tumors on patients’ physical, functional, and psychosocial well-being as experts emphasize effective symptom management and quality-of-life enhancements.

Kimberly C. Chen, DO, MSHLM, dives into the role of genetic testing in identifying patients eligible for gene therapy and explores coverage criteria, clinical validity, and utility considerations crucial for payers and managed care executives.

Emma Ciafaloni, MD, FAAN, describes the key differences among viral vectors used in gene therapy, highlighting their applications and strengths in targeting specific diseases.

Experts explore treatment considerations when treating patients with metastatic breast cancer with elacestrant, including dosing, patient selection, adherence, and treatment duration. Participants also discuss dose modifications, adherence concerns, and how they determine treatment failure.

Explore the facilitation of novel therapy access for desmoid tumors and discover emerging treatments reshaping the landscape.

The criticality of patient education in BTKi use and its impact on treatment adherence is discussed.

Aaron Gerds, MD, MS, reviews the National Comprehensive Cancer Network (NCCN) guideline categories, including evidence, and recommendations for symptomatic high-risk myelofibrosis. He discusses considerations for selecting JAK inhibitors and the threshold for switching treatments based on responses.

Discover how medical institutions provide education on desmoid tumors, ensuring patient referrals and expanding access to innovative therapies.

Eric D. Donnenfeld, MD; discusses the importance of understanding the pathogenesis of Demodex blepharitis to reach a proper diagnosis.

Experts evaluate the financial impact experience by patients receiving BTK inhibitor therapy.

Jessica Nance, MD, MS, discusses maximizing gene therapy efficiency by selecting vectors for gene size, tissue targeting, and low exposure, and focusing on precise promoters for expression.

Experts delve into the fundamentals of gene therapy, covering in vivo and ex vivo methods, and explore cellular function targets for effective treatment of a disease.

Mirna Chehade, MD, MPH, discusses ongoing trials for emerging therapies in eosinophilic esophagitis (EoE), her views on the use of combination therapies, and the importance of shared decision-making for the chronic management of EoE throughout the different phases of a patient’s life.

Experts delve into practical aspects of using elacestrant in later-line treatment of patients with estrogen receptor–positive (ER+)/HER2-negative (HER2–) metastatic breast cancer, including testing for ESR1 mutations, evaluating efficacy, and monitoring for toxicity.

Dr Shamie shares her optimism in the advancement of Demodex Blepharitis treatment.

A review of insurance policies for Demodex blepharitis treatments, along with an analysis of the potential toxicities associated with these treatments.

Clinicians explore disparities and similarities in desmoid tumor treatment approaches between academic and community settings, considering access to clinical trials, shared decision-making, and patient education for better outcomes.

Medical experts illustrate the impact of combination therapy for treatment of CLL and SLL.

Aaron Gerds, MD, MS, discusses key updates in the National Comprehensive Cancer Network (NCCN) guidelines for myelofibrosis, including new treatments such as momelotinib and refined recommendations for different patient populations. He reviews symptom management, spleen size, and supportive care measures for optimal patient outcomes.

Delve into the NCCN guidelines and contemporary treatments for desmoid tumors and explore the multidisciplinary approach, limitations, and current standard care options for enhanced patient outcomes.

With their closing thoughts, the panelists provide their key takeaways from this discussion surrounding the operationalization of bispecifics.

Experts underscore cost relief of bispecific antibodies via medication assistance programs.

Dr Metersky provides his closing thoughts, highlighting key points of emphasis surrounding bronchiectasis care and the future of its treatment landscape.